Prophylactic Measures During Induction for Acute Myeloid Leukemia.

Abstract:

PURPOSE OF REVIEW:Improved management of infectious complications of acute myeloid leukemia (AML) has contributed substantially to the success of care over the past half century. An important approach to reducing infectious complications during the induction period of chemotherapy involves the use of prophylactic antibacterial, antiviral, and antifungal agents targeting likely pathogens. RECENT FINDINGS:There is not a one-size-fits-all approach to prophylaxis; every patient undergoing induction therapy should be evaluated individually and within the context of local microbiologic epidemiology and host risk factors. Pharmacologic and non-pharmacologic interventions as well as novel diagnostic platforms can help mitigate the risk of life-threatening infection in patients with AML who undergo induction chemotherapy.

journal_name

Curr Oncol Rep

journal_title

Current oncology reports

authors

McCarthy MW,Walsh TJ

doi

10.1007/s11912-017-0574-9

subject

Has Abstract

pub_date

2017-03-01 00:00:00

pages

18

issue

3

eissn

1523-3790

issn

1534-6269

pii

10.1007/s11912-017-0574-9

journal_volume

19

pub_type

杂志文章,评审
  • Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.

    abstract:PURPOSE REVIEW:B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas. The toxicity profiles of these medications is distinct from chemoimmunotherapy. Here, we will review the mechanism of action of t...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0694-x

    authors: Rhodes J,Mato A,Sharman JP

    更新日期:2018-04-11 00:00:00

  • Reirradiation of Skull Base Tumors With Advanced Highly Conformal Techniques.

    abstract:PURPOSE OF REVIEW:Skull base reirradiation is challenging due to complex anatomy, enrichment of treatment-resistant clonogens, and increased risk of severe treatment complications. Without local therapy, early mortality is certain and tumor progression can result in debilitating symptoms. Modern radiotherapy advancemen...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0639-9

    authors: Ho JC,Phan J

    更新日期:2017-10-28 00:00:00

  • Inhibition of vascular endothelial growth factor in the treatment of solid tumors.

    abstract::Vascular endothelial growth factor (VEGF) is the term used for a family of tumor-derived angiogenic factors that mediate endothelial proliferation and vascular permeability. Preclinical models have demonstrated the essential nature of VEGF in the angiogenesis of solid tumor growth and metastasis, whereas pathologic in...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0044-9

    authors: Margolin K

    更新日期:2002-01-01 00:00:00

  • Neuroblastoma: biology and staging.

    abstract::Neuroblastoma is the most common extracranial tumor of childhood, with about 650 new cases each year in the United States. The clinical course of neuroblastoma is variable and depends on age at diagnosis, staging, histology, and specific genetic abnormalities, such as MYCN oncogene amplification or aberrations of chro...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0059-6

    authors: Mueller S,Matthay KK

    更新日期:2009-11-01 00:00:00

  • Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.

    abstract::Options for treatment of poor-prognosis or relapsed acute myeloid leukemia (AML) remain limited. Gemtuzumab ozogamicin (Mylotarg, Wyeth-Ayerst, Philadelphia, PA) is an immunoconjugate composed of recombinant humanized murine anti-CD33 antibody linked to calicheamicin, a potent cytotoxic agent. Phase II trials have sho...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0030-2

    authors: Stadtmauer EA

    更新日期:2002-09-01 00:00:00

  • The role of radiotherapy in endometrial cancer: current evidence and trends.

    abstract::Adjuvant treatment of patients with endometrial cancer is tailored to clinical-pathological prognostic factors. Pelvic radiation therapy for stage I endometrial cancer (EC) provides a highly significant improvement of local control, but without survival advantage. Low-risk EC patients have a very favorable prognosis, ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-011-0191-y

    authors: Creutzberg CL,Nout RA

    更新日期:2011-12-01 00:00:00

  • The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore?

    abstract::The establishment of the Intergroup Rhabdomyosarcoma Study (IRS) Committee in 1972 by three extant American pediatric cooperative groups initiated five generations of studies in the multidisciplinary treatment of soft-tissue sarcomas. Taking the lead from the use of vincristine, actinomycin-D, and cyclophosphamide (VA...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0012-z

    authors: Ruymann FB

    更新日期:2003-11-01 00:00:00

  • Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy.

    abstract:PURPOSE OF REVIEW:The aim of this article is to discuss the current role of radiotherapy (RT) for early-stage Hodgkin's lymphoma (HL) in the context of risk-adapted and response-adapted treatment strategy, and describe changes in RT technical approach. RECENT FINDINGS:In low-risk patients, RT could be omitted but, at ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0592-7

    authors: Filippi AR,Levis M,Parikh R,Hoppe B

    更新日期:2017-05-01 00:00:00

  • Intensity-modulated radiation therapy for gastrointestinal tumors.

    abstract::Radiation plays an important role in the multimodal management of tumors of the gastrointestinal (GI) system. Intensity-modulated radiation therapy (IMRT) is a technological development that was introduced to limit the acute and late toxicities commonly associated with conventional radiation therapy. Numerous preclini...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-008-0032-9

    authors: Meyer JJ,Czito BG,Willett CG

    更新日期:2008-05-01 00:00:00

  • Primary Melanoma: from History to Actual Debates.

    abstract:PURPOSE OF REVIEW:This review describes the long scientific background followed to design guidelines and everyday clinical practice applied to melanoma patients. Surgery is the first option to cure melanoma patients (PTS) at initial diagnosis, since primary cutaneous lesions are usually easily resectable. An excisional...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-019-0843-x

    authors: Testori AAE,Blankenstein SA,van Akkooi ACJ

    更新日期:2019-12-19 00:00:00

  • Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.

    abstract:PURPOSE OF REVIEW:Patients with cancer have an elevated risk of cardiovascular disease. This review describes the cardiovascular risks of different cancer therapies and the evidence for cardioprotective strategies. RECENT FINDINGS:Recent studies have provided additional support for the safety and efficacy of dexrazoxa...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00923-w

    authors: Upshaw JN

    更新日期:2020-06-20 00:00:00

  • Current management of anal canal cancer.

    abstract::Squamous cell carcinoma of the anal canal historically has been treated with abdominoperineal resection, resulting in high rates of morbidity and local recurrence. Pioneering work led to the finding that radiation therapy (RT) combined with 5-fluorouracil (5-FU) and mitomycin results in high rates of local control and...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0027-1

    authors: Czito BG,Willett CG

    更新日期:2009-05-01 00:00:00

  • Pediatric palliative care.

    abstract::Pediatric medicine is moving toward a greater appreciation that the delivery of quality medical care involves a partnership including the health care team, the child, and the family. Pediatric medicine now emphasizes the importance of information exchange among these groups. This paper discusses two models for communi...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-007-0061-9

    authors: Weidner NJ

    更新日期:2007-11-01 00:00:00

  • Second-line chemotherapy for non-small-cell lung cancer.

    abstract::Most of the experience with second-line chemotherapy for non-small-cell lung cancer (NSCLC) comes from small phase II trials, which have shown disappointing or inconsistent results. The notable exception has been docetaxel, which has been extensively studied as a second-line therapy for NSCLC. On the basis of consiste...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0016-x

    authors: Fossella FV

    更新日期:2000-01-01 00:00:00

  • Using Information Technology in the Assessment and Monitoring of Geriatric Oncology Patients.

    abstract:PURPOSE OF REVIEW:Older adults with cancer have complex medical needs and often experience higher rates of treatment-related toxicities compared to their younger counterparts. The advent of health information technologies can address multiple gaps in the care of this population. We review the role of existing and emerg...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0672-3

    authors: Loh KP,McHugh C,Mohile SG,Mustian K,Flannery M,Klepin H,Schnall R,Culakova E,Ramsdale E

    更新日期:2018-03-06 00:00:00

  • Advances in Radiation Therapy for Primary and Metastatic Adult Soft Tissue Sarcomas.

    abstract::Soft tissue sarcomas (STS) consist of a heterogeneous group of rare malignancies arising from mesenchymal origin. While surgical resection is the primary treatment for STS, the use of radiotherapy (RT) as an adjunctive modality has been shown to improve oncologic outcomes. Technologic improvements, such as image guida...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-016-0523-z

    authors: Blumenfeld P,Sen N,Abrams R,Wang D

    更新日期:2016-06-01 00:00:00

  • Telemedicine and Palliative Care: an Increasing Role in Supportive Oncology.

    abstract::With the emergence of telemedicine as a routine form of care in various venues, the opportunities to use technology to care for the most vulnerable, most ill cancer patients are extremely appealing. Increasingly, evidence supports early integration of palliative care with standard oncologic care, supported by recent N...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0600-y

    authors: Worster B,Swartz K

    更新日期:2017-06-01 00:00:00

  • Targeting pediatric malignancies for T cell-mediated immune responses.

    abstract::Successful immune targeting of malignancies hinges upon the ability to activate specific T-cell populations to recognize and attack tumor but spare normal vital tissues. Investigators in the field of tumor immunology are currently utilizing at least three distinct approaches toward this goal. In the first approach, mo...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0108-7

    authors: Mackall CL,Helman LJ

    更新日期:2000-11-01 00:00:00

  • Overview of electronic data sharing: why, how, and impact.

    abstract::Electronic data sharing is a critical, but underappreciated, requirement for modern medical informatics systems. This capability is facilitated by acquisition of structured clinical data, but optimized only if this data is stored and transmitted using standardized representations. Most electronic medical record and cl...

    journal_title:Current oncology reports

    pub_type: 杂志文章

    doi:10.1007/s11912-012-0271-7

    authors: Jones RB,Reeves D,Martinez CS

    更新日期:2012-12-01 00:00:00

  • Neoadjuvant therapy for breast cancer: assessing treatment progress and managing poor responders.

    abstract::There is no clear consensus regarding the most effective management of poor responders to neoadjuvant chemotherapy. Intensifying or changing primary systemic treatment has not been shown to offer any benefit. There is a paucity of trials testing the utility of adjuvant chemotherapy in this setting. Adjuvant hormonal t...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0007-5

    authors: Wesolowski R,Budd GT

    更新日期:2009-01-01 00:00:00

  • Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management.

    abstract::The search is on for biomarkers for use in the diagnosis, staging, prognosis, and management of patients with melanoma. As with many types of cancer, the hematogenous spread of melanoma is a bad prognostic sign, and many groups have attempted to detect circulating melanoma cells in patients with different stages of me...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-005-0065-2

    authors: Kounalakis N,Goydos JS

    更新日期:2005-09-01 00:00:00

  • Fertility preservation and management of gonadal failure associated with lymphoma therapy.

    abstract::Treatment with cytotoxic chemotherapy and radiotherapy is associated with significant gonadal damage in men and women. The likelihood of gonadal failure following cytotoxic chemotherapy is dependent on the drug and dose, and in women there is also an effect of age at treatment. Irradiation of the testes or ovaries, ei...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0039-6

    authors: Howell SJ,Shalet SM

    更新日期:2002-09-01 00:00:00

  • Risk assessment models to estimate cancer probabilities.

    abstract::Cancer risk has become a significant research topic due to an increase in statistical risk models built to predict cancer incidence or mortality. Over the past 3 years, 15 models on the development of different types of cancer, including breast, colorectal, prostate, gastric, lung, ovarian, pancreatic, testicular, and...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-007-0071-7

    authors: Johnson CM,Smolenski D

    更新日期:2007-11-01 00:00:00

  • Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.

    abstract::The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells. Since then, a number of additional antibodies have been tested against other B-cell targets, result...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-008-0064-1

    authors: Sikder MA,Friedberg JW

    更新日期:2008-09-01 00:00:00

  • Success at last: a molecular factor that informs treatment.

    abstract::Anaplastic oligodendrogliomas are rare primary brain tumors. However, they respond more effectively to treatment and have a better prognosis than commoner varieties. About 25 year ago, reports emerged that oligodendrogliomas can respond robustly and durably to chemotherapy with procarbazine, lomustine (CCNU), and vinc...

    journal_title:Current oncology reports

    pub_type: 杂志文章

    doi:10.1007/s11912-012-0281-5

    authors: Lassman AB

    更新日期:2013-02-01 00:00:00

  • Preoperative and adjuvant treatment of localized rectal cancer.

    abstract::Although postoperative chemoradiation has a proven role in the treatment of stage II to III localized rectal cancer, recent trials have demonstrated the role of preoperative chemoradiation. A recent randomized trial has shown that preoperative chemoradiation yields higher rates of local control and sphincter preservat...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-006-0016-6

    authors: Das P,Crane CH

    更新日期:2006-05-01 00:00:00

  • Intensity-modulated radiotherapy for carcinoma of the head and neck.

    abstract::Intensity-modulated radiotherapy (IMRT) is the next evolutionary step of three-dimensional conformal radiotherapy (3-DCRT). IMRT plans are generated with computer-optimized nonuniform radiation beam intensities incident on a target or patient. The dose distributions in IMRT show significantly higher conformality compa...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0100-0

    authors: Peñagarícano JA,Papanikolaou N

    更新日期:2003-03-01 00:00:00

  • Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

    abstract::The endothelins (ETs), which include ET-1, ET-2, ET-3, and their receptors ET-A and ET-B, play a major role in tumor growth, proliferation, apoptosis, angiogenesis, and bone metastasis. Atrasentan is a novel and selective inhibitor of ET-1 and ET-A. In vitro and in vivo data show that this oral agent is capable of inh...

    journal_title:Current oncology reports

    pub_type: 杂志文章

    doi:10.1007/s11912-006-0045-1

    authors: Thakkar SG,Choueiri TK,Garcia JA

    更新日期:2006-03-01 00:00:00

  • Molecular genetics of pediatric central nervous system tumors.

    abstract::Recent advances in molecular biology have enhanced our understanding of the pathogenesis of brain tumors, particularly in children. The use of molecular diagnostic tools is quickly becoming a standard component in the diagnosis and classification of brain tumors in children, in addition to providing insight leading to...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-006-0070-0

    authors: Ullrich NJ,Pomeroy SL

    更新日期:2006-11-01 00:00:00

  • Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents.

    abstract::Cyclin-dependent kinases (CDKs) and their related pathways represent some of the most attractive targets in the development of anticancer therapeutics. Among a variety of CDK inhibitors under development, flavopiridol, UCN-01, CYC202, and BMS-387032 are undergoing clinical evaluation based on evidence of preclinical a...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-004-0024-3

    authors: Dai Y,Grant S

    更新日期:2004-03-01 00:00:00